Kinetics of renal function during induction in newly diagnosed multiple myeloma: Results of two prospective studies by the german myeloma study group dsmm

Bachmann F, Schreder M, Engelhardt M, Langer C, Wolleschak D, Muegge LO, Duerk H, Schaefer-Eckart K, Blau IW, Gramatzki M, Liebisch P, Grube M, Metzler I, Bassermann F, Metzner B, Roellig C, Hertenstein B, Khandanpour C, Dechow T, Hebart H, Jung W, Theurich S, Maschmeyer G, Salwender H, Hess G, Bittrich M, Rasche L, Brioli A, Eckardt KU, Straka C, Held S, Einsele H, Knop S (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Book Volume: 13

Pages Range: 1-13

Article Number: 1322

Journal Issue: 6

DOI: 10.3390/cancers13061322

Abstract

Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, pro-vided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex; VCD) or btz, lenalidomide (len), and dex (VRd) or len, adriamycin, and dex (RAD). The minimum required estimated glomerular filtration rate (eGFR) was >30 mL/min. We analyzed the percent change of the renal function using the International Myeloma Working Group (IMWG) criteria and Kidney Disease: Improving Global Outcomes (KDIGO)-defined categories. Results: Seven hundred and seventy-two patients were eligible. Three hundred and fifty-six received VCD, 214 VRd, and 202 RAD. VCD patients had the best baseline eGFR. The proportion of pts with eGFR <45 mL/min decreased from 7.3% at baseline to 1.9% PInd (p < 0.0001). Thirty-seven point one percent of VCD versus 49% of VRd patients had a decrease of GFR (p = 0.0872). IMWG-defined “renal complete response (CRrenal)” was achieved in 17/25 (68%) pts after VCD, 12/19 (63%) after RAD, and 14/27 (52%) after VRd (p = 0.4747). Conclusions: Analyzing a large and representative newly diagnosed myeloma (NDMM) group, we found no difference in CRrenal that occurred independently from the myeloma response across the three regimens. A trend towards deterioration of the renal function with VRd versus VCD may be explained by a better pretreatment “renal fitness” in the latter group.

Authors with CRIS profile

Involved external institutions

Charité - Universitätsmedizin Berlin Germany (DE) Julius-Maximilians-Universität Würzburg Germany (DE) Universitätsklinikum Freiburg Germany (DE) Universitätsklinikum Ulm Germany (DE) Universitätsklinikum Magdeburg A.ö.R. Germany (DE) Universitätsklinikum Jena Germany (DE) St. Barbara-Klinik Hamm Germany (DE) Paracelsus Medizinische Privatuniversität, Nürnberg Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Universitätsklinikum Regensburg Germany (DE) Universitätsklinikum Frankfurt am Main (KGU) Germany (DE) Klinikum rechts der Isar Germany (DE) Pius-Hospital Oldenburg Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Klinikum Bremen-Mitte Germany (DE) Universitätsklinikum Münster Germany (DE) Stauferklinikum Schwäbisch Gmünd Germany (DE) Universitätsklinikum Göttingen Germany (DE) Klinikum der Universität München (Großhadern und Innenstadt) Germany (DE) Klinikum Ernst von Bergmann Germany (DE) Asklepios Klinik Altona Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz Germany (DE) Klinikum Schwabing Germany (DE) ClinAssess Gesellschaft für klinische Forschung mbH Germany (DE)

How to cite

APA:

Bachmann, F., Schreder, M., Engelhardt, M., Langer, C., Wolleschak, D., Muegge, L.O.,... Knop, S. (2021). Kinetics of renal function during induction in newly diagnosed multiple myeloma: Results of two prospective studies by the german myeloma study group dsmm. Cancers, 13(6), 1-13. https://doi.org/10.3390/cancers13061322

MLA:

Bachmann, Friederike, et al. "Kinetics of renal function during induction in newly diagnosed multiple myeloma: Results of two prospective studies by the german myeloma study group dsmm." Cancers 13.6 (2021): 1-13.

BibTeX: Download